Exhibit 31.2

               Certification required by Rule 13a-14(a) or 15d-14
                     of the Securities Exchange Act of 1934

CERTIFICATION

I, Paul J. Van Damme , Vice  President,  Finance  and Chief  Financial  Officer,
certify that:

1.    I have reviewed this annual report on Form 40-F of Vasogen;

2.    Based on my knowledge,  this report does not contain any untrue  statement
      of a material fact or omit to state a material fact  necessary to make the
      statements made, in light of the circumstances under which such statements
      were made,  not  misleading  with  respect  to the period  covered by this
      report;

3.    Based on my  knowledge,  the  financial  statements,  and other  financial
      information  included  in this  report,  fairly  present  in all  material
      respects the financial condition,  results of operations and cash flows of
      the issuer as of, and for, the periods presented in this report;

4.    The  issuer's  other  certifying   officers  and  I  are  responsible  for
      establishing  and  maintaining  disclosure  controls  and  procedures  (as
      defined in Exchange Act Rules  13a-15(e) and 15d-15(e)) for the issuer and
      have:

      a)    Designed such  disclosure  controls and  procedures,  or caused such
            disclosure   controls  and  procedures  to  be  designed  under  our
            supervision,  to ensure that  material  information  relating to the
            issuer, including its consolidated subsidiaries, is made known to us
            by others within those entities,  particularly  during the period in
            which this report is being prepared;

      b)    Evaluated the effectiveness of the issuer's  disclosure controls and
            procedures  and presented in this report our  conclusions  about the
            effectiveness of the disclosure  controls and procedures,  as of the
            end of the period  covered by this report based on such  evaluation;
            and

      c)    Disclosed in this report any change in the issuer's internal control
            over financial  reporting that occurred during the period covered by
            the annual  report that has  materially  affected,  or is reasonably
            likely to  materially  affect,  the issuer's  internal  control over
            financial reporting; and

5.    The issuer's other certifying officers and I have disclosed,  based on our
      most recent  evaluation of internal control over financial  reporting,  to
      the  issuer's  auditors and the audit  committee of the issuer's  board of
      directors (or persons performing the equivalent functions):

      a)    All significant  deficiencies and material  weaknesses in the design
            or operation of internal control over financial  reporting which are
            reasonably  likely to  adversely  affect  the  issuer's  ability  to
            record, process, summarize and report financial information; and

      b)    Any fraud,  whether or not  material,  that  involves  management or
            other employees who have a significant role in the issuer's internal
            control over financial reporting.


/s/ Paul J. Van Damme
------------------------------------------
Paul J. Van Damme
Vice President, Finance and Chief Financial Officer (Principal Financial
Officer), Vasogen Inc.

February 21, 2006